Markets:

Overview

News

Currencies

International

Treasuries

GRAIL, Inc. - Common Stock (NQ:GRAL)

51.32 -50.21 (-49.46%)

Streaming Delayed Price Updated: 1:09 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GRAIL, Inc. - Common Stock

Top movers in Friday's session ↗

Today 12:30 EST

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

Today 10:30 EST

Via Chartmill

Which stocks are moving before the opening bell on Friday? ↗

Today 8:30 EST

Via Chartmill

Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗

Today 7:52 EST

Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.

Via Stocktwits

GRAIL INC (NASDAQ:GRAL) Plummets 47% Despite Narrower-Than-Expected Q4 Loss ↗

February 19, 2026

Via Chartmill

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Why Grail Stock Is Sinking Friday ↗

Today 5:18 EST

GRAIL (NASDAQ: GRAL) shares plunged after the NHS-Galleri trial failed to meet its primary endpoint. Explore the trial results.

Via Benzinga

Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗

Today 3:53 EST

Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume.

Via Stocktwits

Topics ETFs Economy Government

Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

February 19, 2026

From Johnson Fistel, PLLP

Via Business Wire

GRAL Stock Slumps After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses ↗

February 19, 2026

The trial did not show a statistically significant reduction in Stage III-IV cancer diagnoses, the company said.

Via Stocktwits

Topics Artificial Intelligence Death

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

February 19, 2026

Via Chartmill

Here's Why This Exciting Healthcare Stock Popped 13% Today ↗

January 22, 2026

Investors are getting excited by the prospects for Grail's Galleri test in 2026.

Via The Motley Fool

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

Via MarketMinute

Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025 ↗

January 03, 2026

Via MarketBeat

Here's Why Grail Soared, Again, in November ↗

December 02, 2025

A combination of operational improvements and developments at its key rival bolstered the stock recently.

Via The Motley Fool

Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗

November 19, 2025

Via MarketBeat

Why Grail Stock Zoomed Nearly 7% Higher on Monday ↗

November 17, 2025

The company has significant potential with its comprehensive cancer test.

Via The Motley Fool

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

GRAIL (GRAL) Q3 2025 Earnings Call Transcript ↗

November 13, 2025

GRAIL (GRAL) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

GRAIL INC (NASDAQ:GRAL) Q3 2025 Earnings: Tops Revenue and EPS Estimates as Galleri Sales Climb ↗

November 12, 2025

GRAIL (GRAL) Q3 2025 earnings beat estimates on revenue and EPS, sending the stock higher. Strong growth for its Galleri cancer test drove the positive results.

Via Chartmill

Topics Earnings

Here's Why Grail Stock Exploded Higher by 55% in October ↗

November 06, 2025

The company demonstrated tangible progress on its path to profitability.

Via The Motley Fool

Grail Stock Is Up 80% Over the Past Month. Here's Why. ↗

October 23, 2025

This cancer detection test maker just got some great news.

Via The Motley Fool

Grail's CEO Sells 7,200 Shares for nearly $500,000 ↗

October 21, 2025

Via The Motley Fool

Topics Regulatory Compliance

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Topics Artificial Intelligence

Why Is GRAL Stock Rising Today? ↗

October 20, 2025

GRAIL plans to raise about $325 million through a private placement involving both new and existing institutional investors.

Via Stocktwits

Why Grail Stock Soared 14% Higher on Thursday ↗

October 16, 2025

The company is receiving a significant equity investment as a component of a collaboration agreement with a large business partner.

Via The Motley Fool

Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday ↗

October 16, 2025

Via Benzinga

This Cancer Detection Pioneer Is Worth a Look ↗

September 26, 2025

Multicancer detection tests are closing in on FDA approval and potentially major sales.

Via The Motley Fool

GRAIL INC (NASDAQ:GRAL) Reports Mixed Q2 2025 Earnings: Revenue Misses, Loss Narrows ↗

August 12, 2025

GRAIL Inc. (NASDAQ:GRAL) reported Q2 2025 results with revenue of $35.5M missing estimates, but a narrower EPS loss of -$3.18. Galleri test sales grew 21% YoY. Shares fell 2.6% post-earnings....

Via Chartmill

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.